Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.

International journal of clinical oncology - 1 Oct 2024

Yoh Kiyotaka, Azuma Koichi, Hayashi Hidetoshi, Nishio Makoto, Chikamori Kenichi, Ichihara Eiki, Watanabe Yasutaka, Asato Takayuki, Kitagawa Tadayuki, Fram Robert J, Ohe Yuichiro

Abstract excerpt

BACKGROUND: Mobocertinib is a novel, synthetic, orally administered tyrosine kinase inhibitor that inhibits many activated forms of epidermal growth factor receptor (EGFR), including those containing exon 20 insertion (ex20ins) mutations. This study aimed to assess the efficacy of mobocertinib in Japanese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR ex20ins...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to East Asian People

Share to Indoles

Share to Mutagenesis, Insertional

Share to Pyrimidines

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 39190099
DOI: 10.1007/s10147-024-02588-y
PMCID: PMC11420270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.PMID 39190099Read ↗

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy AnalysisSemantic proximity Read ↗

Mobocertinib in non-small cell lung cancer.Semantic proximity Read ↗

A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19).Semantic proximity Read ↗

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung CancerSemantic proximity Read ↗

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancerSemantic proximity Read ↗

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 TrialSemantic proximity Read ↗

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial.Semantic proximity Read ↗

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion MutationsSemantic proximity Read ↗

First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.Semantic proximity Read ↗

Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions.Semantic proximity Read ↗

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidationSemantic proximity Read ↗

[EGFR Exon 20 Insertion Mutation: Research Status and New Treatment Strategies].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.